Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin Chemotherapy

Zanotti, Kristine; Rybicki, Lisa; Kennedy, Alexander W.; Belinson, Jerome L.; Webster, Kenneth; Kulp, Barbara; Peterson, Gertrude; Markman, Maurie

doi:10.1200/jco.2001.19.12.3126

Cited by 149 publications

(103 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In two patients (4.8%), the hypersensitivity reactions occurred at the first exposure and their symptoms were mild. It has been reported that all platinum compounds could induce allergic reactions (Polyzos et al, 2001;Zanotti …”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Kim¹,

Kang²,

Lee³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Kim¹,

Kang²,

Lee³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…9,15,16 Markman et al 16 showed that a negative test substantially decreased the incidence of severe reactions. They also suggested that this test be used as a method of predicting the risk of developing an adverse reaction before carboplatin treatment.…”

Section: Discussionmentioning

confidence: 99%

Successful carboplatin desensitization in patients with proven carboplatin allergy

Confino‐Cohen

Fishman

Altaras

et al. 2005

Cancer

View full text Add to dashboard Cite

We present the first all‐atom model for the structure of a T = 3 virus, pariacoto virus (PaV), which is a nonenveloped, icosahedral RNA virus and a member of the Nodaviridae family. The model is an extension of the crystal structure, which reveals about 88% of the protein structure but only about 35% of the RNA structure. New modeling methods, combining coarse‐grained and all‐atom approaches, were required for developing the model. Evaluation of alternative models confirms our earlier observation that the polycationic N‐ and C‐terminal tails of the capsid proteins must penetrate deeply into the core of the virus, where they stabilize the structure by neutralizing a substantial fraction of the RNA charge. This leads us to propose a model for the assembly of small icosahedral RNA viruses: nonspecific binding of the protein tails to the RNA leads to a collapse of the complex, in a fashion reminiscent of DNA condensation. The globular protein domains are excluded from the condensed phase but are tethered to it, so they accumulate in a shell around the condensed phase, where their concentration is high enough to trigger oligomerization and formation of the mature virus. © 2009 Wiley Periodicals, Inc. Biopolymers 91: 530–538, 2009. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com

show abstract

“…The incidence of HSR in pivotal phase Ⅲ trials of oxaliplatin both in metastatic and adjuvant setting is show in Table 2 [2,10,11] . All platinum compounds are known to cause HSR [12][13][14][15] . Being a platinum derivative, it is not surprising that oxaliplatin can also develop HSR [5][6][7][8][9] .…”

Section: Discussionmentioning

confidence: 99%

“…However, the incidence of HSR to oxaliplatin is rising recently as a result of increasing clinical use both in the adjuvant and metastatic treatment of colorectal cancer. The reactions usually occur after multiple infusions (mean [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] cycles of therapy with variable and unpredictable clinical features [9] . Patients can experience flushing, alterations in heart rate and blood pressure, bronchospasm, back pain, chest discomfort, fever, pruritis, erythema, nausea, and rash [3,5] .…”

Section: Discussionmentioning

confidence: 99%

Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

Saif

Roy²,

Ledbetter³

et al. 2007

WJG

View full text Add to dashboard Cite

Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritis, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9 th and 10 th infusions, she developed fever to a maximum of 38.3℃ with stable hemodynamic status despite medications. During 11 th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8℃, BP dropped to 95/43 mm Hg, pulse of 116/min and O2 saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer.

show abstract

Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin Chemotherapy

Abstract: An easily performed skin test appears to predict patients in whom carboplatin may be safely administered. Treatment modifications based on the results of skin testing may reduce the incidence of HRs in patients receiving repeated courses of carboplatin.

Cited by 149 publications

References 23 publications

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Successful carboplatin desensitization in patients with proven carboplatin allergy

Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

Contact Info

Product

Resources

About